<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02863146</url>
  </required_header>
  <id_info>
    <org_study_id>HALACAP-1406</org_study_id>
    <nct_id>NCT02863146</nct_id>
  </id_info>
  <brief_title>Efficacy of the Use of Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Breast Cancer</brief_title>
  <official_title>Efficacy of the Use of a Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Locally Advanced or Metastatic Breast Cancer Pretreated With Anthracyclines and Taxanes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HALACAP-1406 is a prospective single-centre non-interventional study assessing the&#xD;
      refrigerant helmet use as medical device to prevent alopecia induced by eribulin (Halaven®)&#xD;
      in the conditions of use specified in its marketing authorization. Eribulin will be used&#xD;
      alone for the treatment of the patients having a locally advanced or metastatic breast cancer&#xD;
      which have progressed after at least 1 chemotherapy regimen for their advanced stage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A nurse will meet the patient and present the study, then the patient will be invited to&#xD;
      participate. If the patient is interested, an information note will be given and the&#xD;
      non-opposition of the patient will be collected.&#xD;
&#xD;
      Patients will be registered via a registration form and an inclusion number will be&#xD;
      attributed at each patient.&#xD;
&#xD;
      Eribulin will be used within the framework of its marketing authorization, per cycle of 21&#xD;
      days, at day 1 and day 8.&#xD;
&#xD;
      Modalities of refrigerant helmet use will be set according to the habits of the Oscar Lambret&#xD;
      center with the following rules :&#xD;
&#xD;
        -  Placement of a single-use non-woven hygiene cap on the scalp&#xD;
&#xD;
        -  T-15 minutes: placement of the refrigerant helmet&#xD;
&#xD;
        -  T0: begin of eribulin infusion (duration: 2-5 minutes)&#xD;
&#xD;
        -  T+15 minutes: rinse of the line&#xD;
&#xD;
        -  T+30 minutes: withdrawal of the helmet&#xD;
&#xD;
      Efficacy will be evaluated before treatment and at each eribulin cycle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Alopecia grade after 3 cycles of eribulin according to NCI-CTCAE v4.0</measure>
    <time_frame>on the day 1 of cycle 4</time_frame>
    <description>Efficacy of the refrigerant helmet : Alopecia grade after 3 cycles of eribulin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events graded according to NCI-CTCAE v4.0</measure>
    <time_frame>every 28 days : at day 1 of each cycle during 3 cycles</time_frame>
    <description>Tolerance of the refrigerant helmet : graduation of adverse events lived by patients</description>
  </secondary_outcome>
  <enrollment type="Actual">23</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Metastatic Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Locally advanced or metastatic breast cancer patients treated with eribulin and whose&#xD;
        cancer has progressed after at least 1 chemotherapy regimen for their advanced stage&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patient who has a locally advanced or metastatic breast cancer&#xD;
&#xD;
          -  Indication of Halaven treatment :&#xD;
&#xD;
        patient pretreated with anthracyclines or taxanes, patient who has received at least 1&#xD;
        chemotherapy regimen for their advanced or metastatic stage&#xD;
&#xD;
          -  Patient who has had enough time to have retrieved her hair or whose last chemotherapy&#xD;
             regimen didn't induce alopecia.&#xD;
&#xD;
          -  Aged ≥ 18 years&#xD;
&#xD;
          -  Non-opposition of the patient must have been collected&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Skin metastasis of the scalp&#xD;
&#xD;
          -  Sensitivity to cold, cold agglutinin disease or cryoglobulinemia&#xD;
&#xD;
          -  Impossibility to submit at the study procedures due to geographic, social or mental&#xD;
             reasons&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence VANLEMMENS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Monique Blondel</last_name>
    <role>Study Director</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>February 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2016</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>locally advanced breast cancer</keyword>
  <keyword>alopecia</keyword>
  <keyword>eribulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

